Skip to main content
Home > Week in Review > Other News

Chronological Index of : Other News

 Current Issue
  • WuXi PharmaTech, South Texas Accelerated Research Therapeutics cancer, genomics news

    WuXi PharmaTech Inc. (NYSE:WX) Shanghai, China South Texas Accelerated Research Therapeutics (START), San Antonio, Texas Business: Cancer, Genomics WuXis WuXi NextCODE subsidiary partnered with the San Antonio 1000 …

    Published on 11/23/2015
  • Arena pharmaceuticals news

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Business: Pharmaceuticals Arena will reduce its U.S. workforce by about 80 (35%) by year end and make additional undisclosed cuts at its Arena Pharmaceuticals …

    Published on 11/16/2015
  • Biodel endocrine/metabolic news

    Biodel Inc. (NASDAQ:BIOD), Danbury, Conn. Business: Endocrine/Metabolic Biodel will reduce headcount by 10 (30%) to about 23 and restructure research and quality-related activities to focus on later-stage clinical …

    Published on 11/16/2015
  • Cellectis gene/cell therapy, cancer news

    Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS), Paris, France Business: Gene/Cell therapy, Cancer In April, Cellectis established a subsidiary, Cellectis Inc., at the Alexandria Center for Life Science in New York, N.Y. …

    Published on 11/16/2015
  • Daiichi Sankyo pharmaceuticals news

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Pharmaceuticals Daiichi will cut 1,000-1,200 positions from its U.S. commercial organization. The company said it is restructuring the organization into a …

    Published on 11/16/2015
  • Elusys, Department of Health and Human Services infectious news

    Elusys Therapeutics Inc., Pine Brook, N.J. Department of Health and Human Services, Washington, D.C. Business: Infectious Elusys said it received a $44.9 million order for investigational anthrax therapy Anthim …

    Published on 11/16/2015
  • GlaxoSmithKline, Iron Horse Therapeutics neurology news

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Iron Horse Therapeutics, San Diego, Calif. Business: Neurology Avalon Ventures and GlaxoSmithKline launched build-to-buy company Iron Horse Therapeutics with up to…

    Published on 11/16/2015
  • Horizon Pharma, Express Scripts, Linden Care LLC pharmaceuticals news

    Horizon Pharma plc (NASDAQ:HZNP), Dublin, Ireland Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Linden Care LLC, Woodbury, N.Y. Business: Pharmaceuticals Express Scripts terminated a contract with pharmacy …

    Published on 11/16/2015
  • KaloBios cancer news

    KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO), South San Francisco, Calif. Business: Cancer KaloBios will reduce headcount by about 17 (61%) to about 11 to focus resources on development of lenzilumab (KB003) in chronic …

    Published on 11/16/2015
  • Merck, Pfizer infectious news

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Infectious The U.S. Court of Appeals for the Federal Circuit upheld a district court decision that Mercks antibiotic Cubicin…

    Published on 11/16/2015
  • Unilife drug delivery news

    Unilife Corp. (NASDAQ:UNIS; ASX:UNS), York, Pa. Business: Drug delivery Unilife reduced headcount by about 50 (17%) in September and by a further 20 employees (8%) in October to about 224 employees. The company also …

    Published on 11/16/2015
  • WuXi PharmaTech, Genomics England genomics news

    WuXi PharmaTech Inc. (NYSE:WX), Shanghai, China Genomics England Ltd., London, U.K. Business: Genomics WuXi PharmaTechs WuXi NextCODE subsidiary entered a contract with Genomics England to interpret genomic data from …

    Published on 11/16/2015
  • Affymetrix, Enzo microarrays news

    Affymetrix Inc. (NASDAQ:AFFX), Santa Clara, Calif. Enzo Biochem Inc. (NYSE:ENZ), Farmingdale, N.Y. Business: Microarrays Affymetrix paid Enzo $10 million to settle a patent infringement suit regarding Enzos U.S. Patent …

    Published on 11/9/2015
  • Turing Pharmaceuticals infectious news

    Turing Pharmaceuticals AG, New York, N.Y. Business: Infectious Turing CEO Martin Shkreli said in an interview the company will commit to a modest price reduction of about 10% for toxoplasmosis drug Daraprim …

    Published on 11/9/2015
  • University of Texas MD Anderson Cancer Center cancer news

    University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer M.D. Anderson Cancer Center added B cell lymphoma, colorectal cancer, glioblastoma, high-risk multiple myeloma, HPV associated-cancers and …

    Published on 11/9/2015
  • Valeant Pharmaceuticals, Philidor Rx Services LLC supply/service news

    Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Philidor Rx Services LLC, Hatboro, Pa. Business: Supply/Service Valeant terminated its relationship with specialty pharmacy Philidor, which …

    Published on 11/9/2015
  • Vaxart, Department of Health and Human Services infectious news

    Vaxart Inc., South San Francisco, Calif. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and Development Authority (BARDA) awarded Vaxart a two-year …

    Published on 11/9/2015
  • Berg, Genomics England genomics news

    Berg LLC, Farmingham, Mass. Genomics England Ltd., London, U.K. Business: Genomics Berg said it joined Genomics Englands Genomics Expert Network for Enterprises (GENE) Consortium. The consortium is collaboration among …

    Published on 11/2/2015
  • Celgene, Hayman Capital Management cancer news

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Hayman Capital Management, Dallas, Texas Business: Cancer The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office instituted an inter partes review (IPR…

    Published on 11/2/2015
  • Shire, Hayman Capital Management gastrointestinal news

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Hayman Capital Management, Dallas, Texas Business: Gastrointestinal The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office instituted two inter…

    Published on 11/2/2015
  • AbbVie, Hayman Capital Management cancer news

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Hayman Capital Management, Dallas, Texas Business: Cancer The Patent Trial and Appeals Board (PTAB) of the U.S. Patent and Trademark Office (PTO) denied an inter partes review (…

    Published on 10/26/2015
  • Biogen autoimmune news

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Business: Autoimmune In its 3Q earnings, Biogen said it plans to eliminate some pipeline programs and cut 11% of its 8,000-employee workforce to push higher priority …

    Published on 10/26/2015
  • Cosmo Pharmaceuticals S.p.A., Jazz Pharmaceuticals, Shire, Hayman Capital Management autoimmune, neurology news

    Cosmo Pharmaceuticals S.p.A. (SIX:COPN), Luxembourg, Luxembourg Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Hayman Capital Management, Dallas, Texas Business…

    Published on 10/26/2015
  • Moderna Therapeutics cancer news

    Moderna Therapeutics Inc., Cambridge, Mass. Business: Cancer Moderna launched subsidiary Caperna LLC to develop personalized cancer vaccines using Modernas mRNA vaccine platform. Moderna CMO Tal Zaks will serve as …

    Published on 10/26/2015
  • NewLink, Merck, Department of Health and Human Services infectious news

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and …

    Published on 10/26/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993